The OBR Blog

Introduction:

In an effort to provide you with timely market feedback from ASCO 2012, OBR and MDOutlook Oncology Intelligence are pleased to share results from MDOutlook’s 5th Annual post-ASCO survey fielded among its global network of more than 62,000 cancer providers.

This forth Quick-Poll to be published in the OBR blog explores Prostate Cancer. Take a look back at our previous blog postings to see QuickPolls on other tumor types as well.

Conclusions from the ASCO 2012 Quick Poll on Prostate Cancer

Expected usage of CAD versus IAD in the upcoming year is 3X versus 2.5X more for US and Ex-US respondents, respectively

For chemotherapy-naïve metastatic castration resistant prostate cancer (mCRPC), the expected clinical importance of abiraterone acetate represents a significant therapeutic development for the global oncology community

Use of abiraterone acetate in the neoadjuvant setting is expected to have a slightly lower clinical relevance

No overall differences amongst geographic regions

The new agents, enzalutamide and cabozantinib are both expected to clinically impact treatment approaches for CRPC throughout the world

Ex-US respondents suggest slightly less of an impact for cabozantinib

Disparity amongst US and Ex-US respondents in regards to the expected clinical impact of alpharadin for the treatment of bone metastases in CRPC

US respondents expect alpharadin will greatly impact a small subset of patients

Ex-US respondents expect alpharadin to have a small impact on a moderate amount of patients

Radio-pharmaceuticals are mainly administered from own institutional/hospital nuclear medicine departments

Final Thoughts

Quick polls are a fast way of measuring expected acceptance of clinical data post major medical meetings, and perhaps can be used to make some assumptions about adoption amongst providers. In today’s information hungry environment, the speed at which these polls can be conducted and analyzed can be advantageous for market planning and “pressure testing” acceptance of data amongst key stakeholders.

Introduction:

In an effort to provide you with timely market feedback from ASCO 2012, OBR and MDOutlook Oncology Intelligence are pleased to share results from MDOutlook’s 5th Annual post-ASCO survey fielded among its global network of more than 62,000 cancer providers.

This third Quick-Poll to be published in the OBR blog explores Colorectal Cancer (CRC) & Hepatocellular Carcinoma (HCC). Stay tuned to our blog in the coming weeks as we publish QuickPolls on the other tumor types as well.

Surgical oncologists and interventional radiologists are used in selected patients

Tivozanib, cabozantinib, and lenalidomide are all expected to have some impact on the treatment landscape for HCC

Final Thoughts

Quick polls are a fast way of measuring expected acceptance of clinical data post major medical meetings, and perhaps can be used to make some assumptions about adoption amongst providers. In today’s information hungry environment, the speed at which these polls can be conducted and analyzed can be advantageous for market planning and “pressure testing” acceptance of data amongst key stakeholders.